See more : TinOne Resources Inc. (TORCF) Income Statement Analysis – Financial Results
Complete financial analysis of Lantern Pharma Inc. (LTRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantern Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lippo Malls Indonesia Retail Trust (LPMDF) Income Statement Analysis – Financial Results
- Metal Tiger plc (MTR.L) Income Statement Analysis – Financial Results
- Middlesex Water Company PFD 7% (MSEXP) Income Statement Analysis – Financial Results
- Yangzhou Chenhua New Material Co., Ltd. (300610.SZ) Income Statement Analysis – Financial Results
- iMedia Brands, Inc. (IMBI) Income Statement Analysis – Financial Results
Lantern Pharma Inc. (LTRN)
About Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| Gross Profit | -174.84K | -154.68K | -97.42K | -3.39K | -1.63K | 2.54K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.89M | 8.60M | 7.57M | 2.24M | 953.19K | 572.10K |
| General & Administrative | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Other Expenses | 0.00 | -31.55K | 160.55K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Cost & Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Interest Income | 765.39K | 204.36K | 67.93K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 204.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| EBITDA | -15.79M | -14.42M | -12.27M | -5.90M | -2.43M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.88M | -14.43M | -12.59M | -5.91M | -2.43M | -1.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.92M | 172.81K | 228.48K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -15.96M | -14.26M | -12.36M | -5.91M | -2.43M | -1.73M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -172.81K | -67.93K | -202.91K | -5.00 | 2.54K |
| Net Income | -15.96M | -14.09M | -12.30M | -5.91M | -2.43M | -1.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| EPS Diluted | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| Weighted Avg Shares Out | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
| Weighted Avg Shares Out (Dil) | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET
DALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.
Lantern Pharma to Present at Upcoming Investor Conferences
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern...
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that...
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that...
Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q2 2022 Results - Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margrave – Chief Financial Officer Conference Call Participants Operator Good...
Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it...
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2022 Results - Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate, Finance & Administrative Coordinator Panna Sharma - President & Chief Executive Officer David Margrave - Chief...
Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET
DALLAS, April 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development,...
Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting
LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, skin, and breast cancers. Brain metastases in the U.S. can occur in 10-30% of all cancer cases and are diagnosed in over 100,000 patients each year.
Source: https://incomestatements.info
Category: Stock Reports